Literature DB >> 19430886

Investigation of immunosuppressive mechanisms in a mouse glioma model.

Alexander Ksendzovsky1, Douglas Feinstein, Ryan Zengou, Anthony Sharp, Paul Polak, Terry Lichtor, Roberta P Glick.   

Abstract

The development of an immune competent mouse model for the study of immunosuppressive mechanisms is important for improving the efficacy of brain tumor immunotherapy. In the present study we investigated regulatory T cells (Tregs), TGF-beta1 and other putative immunosuppressive cytokines using GL261 mouse glioma in C57BL mice. We explored whether tumor growth factor-beta1 (TGF-beta1) is expressed and secreted by glioma cells constitutively or in response to a T-cell mediated immunity (simulated by conditioned media from T cells (TCM) activated by anti-CD3 antibody). We also investigated TGF-beta1's role in Treg mediated immunosuppression by quantifying TGF-beta1secretion from T regulatory cells (Tregs) co-incubated with GL261 cells as compared to Tregs alone. Finally, we studied other newly identified cytokines that were secreted preferentially by glioma cells in response to CD3 activated TCM versus cytokines secreted by glioma cells in absence of T-cell activation (naïve TCM). TGF-beta1expression was studied using RT-PCR and secretion was quantified using ELISA. A 308 protein cytokine array was used to identify and quantify cytokine expression. TGF-beta1expression and secretion from glioma cells was found to be up-regulated by conditioned media from CD3-activated T cells, suggesting that this immunosuppressive cytokine is not secreted constitutively but in response to immunity. TGF-beta1 was not found to be differentially secreted by Tregs co-incubated with glioma cells as compared to Tregs alone. This data suggest that TGF-beta1immunosupppression may not be a Treg dependent mechanism in this glioma model. Finally, the cytokine array elucidated several other cytokines which were up-regulated or down-regulated by CD3-activated TCM. These results have several implications for enhancing immunotherapy treatment, including the potential benefit of TGF-beta1inhibition in conjunction with immunotherapy, as well as the illumination of several other potential cytokine targets to be explored as shown by the cytokine array.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430886     DOI: 10.1007/s11060-009-9884-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  The functional role of the ELR motif in CXC chemokine-mediated angiogenesis.

Authors:  R M Strieter; P J Polverini; S L Kunkel; D A Arenberg; M D Burdick; J Kasper; J Dzuiba; J Van Damme; A Walz; D Marriott
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

Review 2.  TGF beta signalling and its role in tumour pathogenesis.

Authors:  Bozena Kaminska; Aleksandra Wesolowska; Malgorzata Danilkiewicz
Journal:  Acta Biochim Pol       Date:  2005-06-25       Impact factor: 2.149

3.  Bioimmunoassays for proinflammatory cytokines involving cytokine-induced cellular adhesion molecule expression in human glioblastoma cell lines.

Authors:  A Meager
Journal:  J Immunol Methods       Date:  1996-04-19       Impact factor: 2.303

4.  Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

Authors:  Peter E Fecci; Hidenobu Ochiai; Duane A Mitchell; Peter M Grossi; Alison E Sweeney; Gary E Archer; Thomas Cummings; James P Allison; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Authors:  Peter E Fecci; Alison E Sweeney; Peter M Grossi; Smita K Nair; Christopher A Learn; Duane A Mitchell; Xiuyu Cui; Thomas J Cummings; Darell D Bigner; Eli Gilboa; John H Sampson
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

6.  Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.

Authors:  Terry Lichtor; Roberta P Glick; Katherine Tarlock; Shannon Moffett; Elizabeth Mouw; Edward P Cohen
Journal:  Cancer Gene Ther       Date:  2002-05       Impact factor: 5.987

Review 7.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells.

Authors:  Leonie S Taams; Jocea M R van Amelsfort; Machteld M Tiemessen; Kim M G Jacobs; Esther C de Jong; Arne N Akbar; Johannes W J Bijlsma; Floris P J G Lafeber
Journal:  Hum Immunol       Date:  2005-03       Impact factor: 2.850

9.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.

Authors:  D D Taub; A R Lloyd; K Conlon; J M Wang; J R Ortaldo; A Harada; K Matsushima; D J Kelvin; J J Oppenheim
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  Human Mig chemokine: biochemical and functional characterization.

Authors:  F Liao; R L Rabin; J R Yannelli; L G Koniaris; P Vanguri; J M Farber
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  8 in total

1.  Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.

Authors:  Ming Xu; Yu Yao; Wei Hua; Zhebao Wu; Ping Zhong; Ying Mao; Liangfu Zhou; Feifei Luo; Yiwei Chu
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

2.  Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.

Authors:  Aaron J Clark; Michael Safaee; Taemin Oh; Michael E Ivan; Vamsi Parimi; Rintaro Hashizume; Tomoko Ozawa; Charles D James; Orin Bloch; Andrew T Parsa
Journal:  J Transl Med       Date:  2014-12-03       Impact factor: 5.531

3.  Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma.

Authors:  Aaron J Clark; Shayan Fakurnejad; Quanhong Ma; Rintaro Hashizume
Journal:  J Vis Exp       Date:  2016-01-15       Impact factor: 1.355

4.  Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.

Authors:  Benjamin H Beck; Hyunggoon Kim; Rebecca O'Brien; Martin R Jadus; G Yancey Gillespie; Gretchen A Cloud; Neil T Hoa; Catherine P Langford; Richard D Lopez; Lualhati E Harkins; Lawrence S Lamb
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

Review 5.  Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery.

Authors:  Xin-Qi Teng; Jian Qu; Guo-Hua Li; Hai-Hui Zhuang; Qiang Qu
Journal:  Front Cell Dev Biol       Date:  2022-07-08

6.  Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model.

Authors:  Sadhak Sengupta; Suvobroto Nandi; Enal S Hindi; Derek A Wainwright; Yu Han; Maciej S Lesniak
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

7.  Akt and c-Myc induce stem-cell markers in mature primary p53⁻/⁻ astrocytes and render these cells gliomagenic in the brain of immunocompetent mice.

Authors:  Josefine Radke; Ginette Bortolussi; Axel Pagenstecher
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

8.  GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models.

Authors:  Victoria E Sanchez; John P Lynes; Stuart Walbridge; Xiang Wang; Nancy A Edwards; Anthony K Nwankwo; Hannah P Sur; Gifty A Dominah; Arnold Obungu; Nicholas Adamstein; Pradeep K Dagur; Dragan Maric; Jeeva Munasinghe; John D Heiss; Edjah K Nduom
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.